Cargando…
Subgroups in the treatment of nasal polyposis with dupilumab: A retrospective study
Dupilumab has been shown to be safe and effective in treating chronic rhinosinusitis with polyposis (CRSwNP). There is to this date no published data whether subgroups like patients with aspirin exacerbated respiratory disease (AERD), increased histologic eosinophilia or elevated blood eosinophil or...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9666224/ https://www.ncbi.nlm.nih.gov/pubmed/36397403 http://dx.doi.org/10.1097/MD.0000000000031031 |
_version_ | 1784831455776473088 |
---|---|
author | Bertlich, Mattis Freytag, Saskia Dombrowski, Tobias Jurmeister, Philipp Spiegel, Jennifer Lee Bertlich, Ines Ihler, Friedrich Weiss, Bernhard G. Haubner, Frank Gröger, Moritz |
author_facet | Bertlich, Mattis Freytag, Saskia Dombrowski, Tobias Jurmeister, Philipp Spiegel, Jennifer Lee Bertlich, Ines Ihler, Friedrich Weiss, Bernhard G. Haubner, Frank Gröger, Moritz |
author_sort | Bertlich, Mattis |
collection | PubMed |
description | Dupilumab has been shown to be safe and effective in treating chronic rhinosinusitis with polyposis (CRSwNP). There is to this date no published data whether subgroups like patients with aspirin exacerbated respiratory disease (AERD), increased histologic eosinophilia or elevated blood eosinophil or IgE-levels benefit greater from dupilumab therapy. Moreover, there is no data comparing the efficacy of functional endoscopic sinus surgery (FESS) with dupilumab therapy. We conducted a retrospective chart review of all patients that were treated at a tertiary referral center for CRswNP with dupilumab. We also contacted the patients with a questionnaire to evaluate the efficacy of previous surgeries and dupilumab therapy by visual analogue scale (VAS) and the glasgow benefit inventory (GBI) as well as report on side effects. Overall, 75 patients were included in the study at hand that reported back 138 times. While dupilumab treatment was efficient, we found no systematic evidence of greater efficacy of dupilumab in patients with AERD, histologic eosinophilia or increased blood eosinophil or IgE-levels. All patients showed a considerable decrease in subjective burden of disease, objective smell tests and endoscopic findings. From the patients point of view, dupilumab therapy showed greater efficacy both in the VAS and the GBI overall and all subcategories but “social support.” Dupilumab is efficient in treating CRSwNP; this effect is independent from disease characteristics like AERD, histologic eosinophilia, serum IgE-levels or eosinophil counts. There seems to be a group of patients that benefit greater from dupilumab therapy compared to FESS. |
format | Online Article Text |
id | pubmed-9666224 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-96662242022-11-16 Subgroups in the treatment of nasal polyposis with dupilumab: A retrospective study Bertlich, Mattis Freytag, Saskia Dombrowski, Tobias Jurmeister, Philipp Spiegel, Jennifer Lee Bertlich, Ines Ihler, Friedrich Weiss, Bernhard G. Haubner, Frank Gröger, Moritz Medicine (Baltimore) 6000 Dupilumab has been shown to be safe and effective in treating chronic rhinosinusitis with polyposis (CRSwNP). There is to this date no published data whether subgroups like patients with aspirin exacerbated respiratory disease (AERD), increased histologic eosinophilia or elevated blood eosinophil or IgE-levels benefit greater from dupilumab therapy. Moreover, there is no data comparing the efficacy of functional endoscopic sinus surgery (FESS) with dupilumab therapy. We conducted a retrospective chart review of all patients that were treated at a tertiary referral center for CRswNP with dupilumab. We also contacted the patients with a questionnaire to evaluate the efficacy of previous surgeries and dupilumab therapy by visual analogue scale (VAS) and the glasgow benefit inventory (GBI) as well as report on side effects. Overall, 75 patients were included in the study at hand that reported back 138 times. While dupilumab treatment was efficient, we found no systematic evidence of greater efficacy of dupilumab in patients with AERD, histologic eosinophilia or increased blood eosinophil or IgE-levels. All patients showed a considerable decrease in subjective burden of disease, objective smell tests and endoscopic findings. From the patients point of view, dupilumab therapy showed greater efficacy both in the VAS and the GBI overall and all subcategories but “social support.” Dupilumab is efficient in treating CRSwNP; this effect is independent from disease characteristics like AERD, histologic eosinophilia, serum IgE-levels or eosinophil counts. There seems to be a group of patients that benefit greater from dupilumab therapy compared to FESS. Lippincott Williams & Wilkins 2022-11-11 /pmc/articles/PMC9666224/ /pubmed/36397403 http://dx.doi.org/10.1097/MD.0000000000031031 Text en Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC) (https://creativecommons.org/licenses/by-nc/4.0/) , where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. |
spellingShingle | 6000 Bertlich, Mattis Freytag, Saskia Dombrowski, Tobias Jurmeister, Philipp Spiegel, Jennifer Lee Bertlich, Ines Ihler, Friedrich Weiss, Bernhard G. Haubner, Frank Gröger, Moritz Subgroups in the treatment of nasal polyposis with dupilumab: A retrospective study |
title | Subgroups in the treatment of nasal polyposis with dupilumab: A retrospective study |
title_full | Subgroups in the treatment of nasal polyposis with dupilumab: A retrospective study |
title_fullStr | Subgroups in the treatment of nasal polyposis with dupilumab: A retrospective study |
title_full_unstemmed | Subgroups in the treatment of nasal polyposis with dupilumab: A retrospective study |
title_short | Subgroups in the treatment of nasal polyposis with dupilumab: A retrospective study |
title_sort | subgroups in the treatment of nasal polyposis with dupilumab: a retrospective study |
topic | 6000 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9666224/ https://www.ncbi.nlm.nih.gov/pubmed/36397403 http://dx.doi.org/10.1097/MD.0000000000031031 |
work_keys_str_mv | AT bertlichmattis subgroupsinthetreatmentofnasalpolyposiswithdupilumabaretrospectivestudy AT freytagsaskia subgroupsinthetreatmentofnasalpolyposiswithdupilumabaretrospectivestudy AT dombrowskitobias subgroupsinthetreatmentofnasalpolyposiswithdupilumabaretrospectivestudy AT jurmeisterphilipp subgroupsinthetreatmentofnasalpolyposiswithdupilumabaretrospectivestudy AT spiegeljenniferlee subgroupsinthetreatmentofnasalpolyposiswithdupilumabaretrospectivestudy AT bertlichines subgroupsinthetreatmentofnasalpolyposiswithdupilumabaretrospectivestudy AT ihlerfriedrich subgroupsinthetreatmentofnasalpolyposiswithdupilumabaretrospectivestudy AT weissbernhardg subgroupsinthetreatmentofnasalpolyposiswithdupilumabaretrospectivestudy AT haubnerfrank subgroupsinthetreatmentofnasalpolyposiswithdupilumabaretrospectivestudy AT grogermoritz subgroupsinthetreatmentofnasalpolyposiswithdupilumabaretrospectivestudy |